Quantitative assessment of antibodies in Covid-19 is becoming increasingly important. It provides information on the actual spread
of infection in the population and enables characterization of a vaccine-induced immune response.

Of particular interest is the determination of antibodies targeting the receptor-binding domain (RBD) in the viral spike 1 protein since these antibodies show neutralizing properties; they are able to suppress the attachment of the virus to the host cell and thus its infection. The new SARS-CoV-2 UTAB FS (UTAB = Universal Total AntiBody) launched by DiaSys, is an immunoturbidimetric test for quantitative determination of total antibodies in COVID-19. The test is characterized by high specificity and sensitivity and shows no cross-reactivity with antibodies present to other seasonal cold pathogens from the coronavirus group. The liquid stable, ready-to-use reagent with matched calibrators, controls and a sample dilution matrix may be used on almost all clinical chemistry analyzers, providing comparable results and, therefore, enables reliable monitoring of patients.